• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

High response rates observed with novel therapy for HCV infection

byAli Shahbaz
April 17, 2014
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. A single-tablet regimen of ledipasvir and sofosbuvir produced high rates of sustained virologic response among patients with chronic hepatitis C virus genotype 1 infection who had previously failed conventional interferon therapy. 

2. No patient discontinued therapy due to an adverse event. 

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Since the introduction of antiviral therapy for patients with hepatitis C virus (HCV) infection became available 30 years ago, compliance and efficacy of such therapy has been a challenge for health care providers. Many of the conventional drugs available produce common side effects and contraindications that limit the therapeutic response that can be achieved. In this study, researchers introduced a new HCV NS5A inhibitor, ledipasvir, combined in a single-tablet dose with the nucleotide polymerase inhibitor, sofosbuvir. The drug was administered once daily to patients diagnosed with chronic HCV genotype 1 infection. The novel therapy can be given for a relatively short time period to achieve a pharmacological response; however, a significant barrier remains for the availability of these drugs – cost.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

In-Depth [randomized controlled trial]: A total of 551 patients from 64 sites across the United States underwent initial recruitment, with 440 eventually being administered treatment in this open-label study. These patients were above the age of 18 with chronic HCV infection and had not had a sustained virologic response to conventional interferon therapy.

The two drugs were given as an oral dose in a single tablet. Patients were randomized to one of four treatment groups: ledipasvir-sofosbuvir for 12 weeks, ledipasvir-sofosbuvir plus ribavarin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or lesipasvir-sofosbuvir plus ribavarin for 24 weeks. Among these groups, the rates of sustained virologic response at 12 weeks after the end of therapy were 94% (95% CI, 87 to 97), 96% (95% CI, 91 to 99), 99% (95% CI, 95 to 100), and 99% (95% CI, 95 to 100), respectively. The majority of the patients in each treatment group encountered sides effects that were largely mild to moderate in severity.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: hepatitis CinterferonLedipasvirsofosbuvir
Previous Post

Broad decline in incidence rate of diabetes-related complications in US

Next Post

The DASH trial: Diet change significantly reduces blood pressure [Classics Series]

RelatedReports

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
#VisualAbstract Low-PV study: Adding ropeginterferon alfa-2b to phlebotomy and aspirin shows improvement in response rates for treatment of polycythaemia vera in low-risk patients
StudyGraphics

#VisualAbstract Low-PV study: Adding ropeginterferon alfa-2b to phlebotomy and aspirin shows improvement in response rates for treatment of polycythaemia vera in low-risk patients

February 12, 2021
Next Post
Classics Series, Landmark Trials in Medicine

The DASH trial: Diet change significantly reduces blood pressure [Classics Series]

Wound surgical device found ineffective at infection control: ROSSINI Trial

Initial kidney transplant factors may provide insight into retransplant success

Classics Series, Landmark Trials in Medicine

Quadrivalent HPV vaccine in young women [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.